- Home
- FBRX vs AQST Comparison
FBRX vs AQST Comparison
Compare FBRX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRX | AQST |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 504.0M |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FBRX | AQST |
|---|---|---|
| Price | $22.25 | $4.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $67.00 | $9.00 |
| AVG Volume (30 Days) | 194.1K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $7.78 | $2.22 |
| 52 Week High | $35.80 | $7.55 |
Technical Indicators
Market Signals| Indicator | FBRX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 51.26 |
| Support Level | $10.38 | $3.70 |
| Resistance Level | $22.61 | $4.38 |
| Average True Range (ATR) | 2.22 | 0.21 |
| MACD | -0.51 | -0.01 |
| Stochastic Oscillator | 27.81 | 25.00 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.